2012 Pilot Grant Request for Applications

1. Program Objective
This Request for Applications (RFA) is intended to support biological and clinical research projects that are Prostate Cancer specific/exclusive in nature.

2. Mechanisms of Support
NEW: This year the value of the Pilot Grant has been increased to a maximum value of $150,000 over 2.5 years

3. Program Eligibility
In order to apply for this award, applicants must:
Hold a faculty position with a Canadian university, teaching hospital or cancer care institution
NEW: This year PCC will be reviewing Established Investigators (those with more than 8 years of research experience within a faculty position) separately from New Investigators (those with up to 8 years of experience within a faculty position)

4. Applications
To apply, applicants must fill out an online application form which will be found on the Prostate Cancer Canada website, www.prostatecancer.ca onJanuary 3, 2012.

5. Important Dates                           
Competition Opens January 3, 2012
Applications Deadline March 30, 2012 at 5p.m. EST
Notice of Decision June 29, 2012
Funding Start Date July 3, 2012

6. Contact
Joanne Reynolds
joanne.reynolds@prostatecancer.ca
Prostate Cancer Canada 
2 Lombard Street, 3rd Floor
Toronto, Ontario, M5C 1M1
416-441-2131 Ext.  226
1-888-255-0333
www.prostatecancer.ca

 

 
Support PSA Tests


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
Prostate cancer researchers develop personalized genetic test to accurately predict recurrence risk

TORONTO, ON - November 13, 2014 – Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. More

Prostate Cancer Canada reminds men that early detection using ‘Smart Screening’ for prostate cancer

Toronto, ON – October 27, 2014 – Prostate Cancer Canada responds today to guidelines released from The Canadian Task Force on Preventive Health Care (CTFPHC) recommending that the Prostate Specific Antigen (PSA) test should be eliminated as a screening tool for prostate cancer. More


Click here for news archive